Our Search for Better Treatments for Wilms Tumor Published in Communications Biology

Our study, Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin, is published in Communications Biology.

The work establishes patient-derived Wilms tumor cell lines as faithful preclinical models, identifies XPO1 as a therapeutic vulnerability through loss-of-function screening, and demonstrates that combining the FDA-approved XPO1 inhibitor KPT-330 with doxorubicin produces durable remissions in vivo — findings that have contributed to an active Phase II clinical trial NCT05985161.

The manuscript can be found online.